Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) of 1 of the following subtypes:
• * Squamous cell carcinoma
• * Adenocarcinoma (including bronchoalveolar cell)
• * Large cell anaplastic carcinoma (including giant and clear cell carcinomas)
• * Poorly differentiated/not otherwise specified NSCLC
• Stage IIIA (T1-2, N2, M0 or T3, N1-2, M0) or IIIB (T4, any N, M0 or any T, N2-3, M0)
• * If the largest mediastinal node is \< 2.0 cm in diameter and this is the basis for stage III disease, then at least 1 of the nodes must be cytologically or histologically positive
• Unresectable disease
• * No totally resected tumors
• Tumors adjacent to a vertebral body allowed provided all gross disease can be encompassed in the radiation boost field and the boost volume is limited to \< 50% of the ipsilateral lung volume
• Measurable disease
• Transudate, cytologically negative, non-bloody pleural effusions allowed provided the tumor can be encompassed within a reasonable field of radiotherapy
• * Pleural effusions seen on a chest CT scan are allowed provided they are not visible on a chest x-ray and are too small to tap
• No asymptomatic or symptomatic brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Zubrod 0-1
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 9 g/dL (transfusion independent)
• Hepatic
• Bilirubin ≤ 1.5 mg/dL
• SGOT (serum glutamic oxaloacetic transaminase) or SGPT (serum glutamate pyruvate transaminase) ≤ 3 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 2.5 times ULN
• Renal
• Creatinine ≤ 2.0 mg/dL
• Cardiovascular
• No significant history of cardiac disease
• No uncontrolled hypertension
• No unstable angina
• No uncompensated congestive heart failure
• No myocardial infarction within the past year
• No cardiac ventricular arrhythmias requiring medication
• LVEF (left ventricular ejection fraction) normal by MUGA (multi-gated acquisition) scan or echocardiogram
• Pulmonary
• No history of interstitial pneumonitis
• No history of severe chronic obstructive pulmonary disease requiring 3 or more hospitalizations within the past year
• FEV\_1 ≥ 1,200 cc
• No active pulmonary infection unresponsive to conventional antibiotics
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 4 weeks after study therapy
• Glucose ≤ 2 times ULN
• No more than 5% weight loss within the past 3 months
• No known allergy to murine proteins or Cremophor EL
• No neuropathy grade 2 or greater
• No other malignancy within the past 2 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other in situ cancers
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No prior drugs that target the epidermal growth factor receptor pathway
• No prior chimerized monoclonal antibody therapy
• No other concurrent immunotherapy
• No concurrent colony-stimulating factors (i.e., filgrastim \[G-CSF\] and sargramostim \[GM-CSF\])
• * Concurrent epoetin alfa allowed
• Chemotherapy
• No prior systemic chemotherapy
• No other concurrent chemotherapy
• Endocrine therapy
• No concurrent hormonal therapy except hormones for non-disease-related conditions (e.g., insulin for diabetes) or steroids for acute symptom management, adrenal failure, septic shock, or as antiemetics
• Radiotherapy
• No prior thoracic or neck radiotherapy
• No concurrent intensity-modulated radiotherapy
• Surgery
• Recovered from prior exploratory thoracotomy
• No prior surgical resection of the present cancer
• Other
• More than 30 days since prior participation in another clinical trial
• No concurrent participation in another clinical trial
• No other concurrent anticancer therapy
• No amifostine during or for 3 months after study radiotherapy